Gottlieb previews drug price policy

The Trump administration’s drug pricing policy will include a “framework” to dismantle rules and restrictions that “shield parts of the drug industry from more vigorous competition,” FDA Commissioner Scott Gottlieb said Thursday.

Speaking at the Food and Drug Law Institute annual meeting, he said the plan will include “changes to the pricing mechanisms in [Medicare] Part D.” These changes, he added, will create “profound modernization of the program” that will “put us more firmly on a footing to defend the idea that brisk competition should be the vehicle by which we seek to lower drug costs.”...